Yilmaz M, Celik U, Hascicek S. Radiation recall dermatitis with dabrafenib and trametinib: A case report. World J Clin Cases 2020; 8(3): 522-526 [PMID: 32110661 DOI: 10.12998/wjcc.v8.i3.522]
Corresponding Author of This Article
Mesut Yilmaz, MD, Doctor, Medical Oncology Department, Bakırköy Sadi Konuk Training and Research Hospital, Istanbul 34144, Turkey. mesutyilmaz12@yahoo.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 6, 2020; 8(3): 522-526 Published online Feb 6, 2020. doi: 10.12998/wjcc.v8.i3.522
Radiation recall dermatitis with dabrafenib and trametinib: A case report
Mesut Yilmaz, Ugur Celik, Seyhan Hascicek
Mesut Yilmaz, Medical Oncology Department, Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul 34144, Turkey
Ugur Celik, Dermatology Department, Medipol Kosuyolu Hospital, Istanbul 34134, Turkey
Seyhan Hascicek, Pathology Department, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul 34134, Turkey
Author contributions: Yilmaz M and Celik U contributed equally to this work; Yilmaz M designed the case report; Hascicek S carried out pathological evaluations; Yilmaz M wrote the paper.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Mesut Yilmaz, MD, Doctor, Medical Oncology Department, Bakırköy Sadi Konuk Training and Research Hospital, Istanbul 34144, Turkey. mesutyilmaz12@yahoo.com
Received: October 20, 2019 Peer-review started: October 20, 2019 First decision: November 13, 2019 Revised: December 9, 2019 Accepted: December 14, 2019 Article in press: December 14, 2019 Published online: February 6, 2020 Processing time: 108 Days and 11.7 Hours
Abstract
BACKGROUND
Radiation recall dermatitis has been defined as the “recalling” by skin of previous radiation exposure in response to the administration of certain response-inducing drugs. Although the phenomenon is relatively well known in the medical world, an exact cause has not been documented.
CASE SUMMARY
Here, we report the rare occurrence of radiation recall dermatitis after palliative radiotherapy for bone metastases in a metastatic melanoma patient treated with a combination of dabrafenib and trametinib.
CONCLUSION
We present a case of radiation recall dermatitis after completion of palliative radiotherapy while being treated with a combination of dabrafenib and trametinib. This is a very rare toxic event, and there is insufficient data to describe prevention strategies. Increased awareness and reporting of cases will help to better explain the association between targeted therapy and the radiation recall phenomenon.
Core tip: Radiation recall dermatitis is a very rare toxic event. Here we report a case of this phenomenon after completion of palliative radiotherapy while being treated with a combination of dabrafenib and trametinib.
